---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-209296"
form_type: "8-K"
ticker: "DCTH"
cik: "0000872912"
company_name: "DELCATH SYSTEMS, INC."
filed_at: "2024-08-29T23:59:59+00:00"
generated_at: "2026-05-31T07:05:14.737988+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Delcath Systems Announces Positive Independent Study Results for Liver-Directed Therapy in Uveal Melanoma

## Summary
- Study of 167 patients showed median melanoma-specific survival of 28 months with first-line liver-directed therapy vs 10 months with systemic therapy.
- Patients diagnosed 2016-2021 receiving liver-directed therapy had median MSS of 30 months, compared to 20 months for 2005-2015 cohort.
- CHEMOSAT Hepatic Delivery System was used in the study; 30 of 56 patients in 2016-2021 period received CHEMOSAT.
- Study published in Therapeutic Advances in Medical Oncology, conducted by University of Tübingen researchers.

## SEC filing metadata
- accession: 0001193125-24-209296
- form_type: 8-K
- ticker: DCTH
- cik: 0000872912
- company_name: DELCATH SYSTEMS, INC.
- filed_at: 2024-08-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872912/000119312524209296/0001193125-24-209296-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872912/000119312524209296/d848222d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-209296
- JSON: https://secwatch.observer/filing/0001193125-24-209296.json
- Plain text: https://secwatch.observer/filing/0001193125-24-209296.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.